I've considered buying back in several times, but
have not--I'm not sure that the way they handled
975 was the best way to go about it. Biotech stocks
crash all the time when a molecule fails, that is
just part of the risk reward profile of the sector.
But I wonder if Anadys dragged things along unusually
long--which snared me. Now if you can find a chemist
that says it looked all on the up and up...
From last year this is the soft of thing they laid
out for shareholders The recently initiated study,
which utilizes a new crystalline form of ANA975 developed
by Novartis, should further the understanding of the
toxicology profile of ANA975
I think that the fellow who goes by the handle DueDiligence
correctly sniffed out the trouble Anadys was in with that
particular molecule. I wont speak for him further, but I
suspect more astute biotech investors than myself knew
the molecule was dead. I on the other hand love to play
the contrarian and I found their press releases reassuring.
Needless to say, I took a loss on ANDS.
Presumably the management team is different now, but
I think you could probably let a little more time
elapse--maybe when the events of last summer are a
good year behind them?
They've changed CEO twice since then, right? Maybe
that clears the board and maybe this is indeed the
right time to get in, but I for one am staying clear
of it, no matter the price.
edit, now that I think about it, I did put ANDS into
my biotech contest picks, ha!
Message 24178745
But that is just because I've followed the story and it
keeps it in my radar. I have two classes of stocks
as my contest picks, speculative submicrocap stocks,
and speculative biotechs price above $5 a share that
have an air of respectability, heh.
As I said, I've considered it for purchase in the real
world, and passed, bwdik? |
